Trial Profile

A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions
Sponsors Alteogen

Most Recent Events

08 Mar 2021 According to an Alteogen media release, the results from the phase 1 trial in Korea will support the design of the phase 3 trial and potentially provide a path to a shorter phase 3 trial.
08 Mar 2021 Results published in the Media Release
08 Mar 2021 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com